Drug – bio-affecting and body treating compositions – Dentifrices – Fluorine or fluorine compound containing
Reexamination Certificate
2007-09-14
2011-11-08
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Dentifrices
Fluorine or fluorine compound containing
C435S141000, C514S021800
Reexamination Certificate
active
08052961
ABSTRACT:
Disclosed are compounds having the structure:wherein R1aand R1bare independently H, alkyl, F, or fluoroalkyl; wherein R2a, R2b, R2a′, and R2b′are independently H, alkyl, F, fluoroalkyl, aryl, or alkenyl; wherein R3is OH, alkoxyl, NH2, alkylamino, or dialkylamino; wherein R4aand R4bare independently H, alkyl, acyl, or alkyloxycarbonyl; wherein R11, R12, R13, R21, R22, and R23are independently H, alkyl, F, or fluoroalkyl; and wherein C0, C1, C2 and C2′ are independently chiral or achiral. Also disclosed are processes for making a fluorinated β-amino acid comprising the steps of: providing a diol; treating the diol with a thionyl halide with oxidative workup; reacting the product with an azide salt to yield an azido group; oxidizing the product to yield a carboxyl group; and reducing the azido group to yield an amino group.
REFERENCES:
Fustero, 2002, Journal of Organic Chemistry, 67, 4667-4679.
Renaud, 1968, Canadian Journal of Chemistry, 46, 385-390.
Aguilera et al. Novel disaccharide inhibitors of human glioma cell division. J. Med. Chern. 1998,41,4599-4606.
Bilgicer et al. De novo design of defined helical bundles in membrane environments. Proc. Natl. Acad. Scis. USA 2004, 101: 15324-15329.
Bohm et al. Fluorine in medicinal chemistry. ChemBioChem. 2004, 5, 637-643.
Bolo et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000, 23, 428-438.
Christensen et al. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy. Brain. Res. 1999; 834, 1-5.
Cybulla et al. End-stage renal disease after treatment with 90Y-DOTATOC. Eur. J. Nucl. Med.28, 1552-1554,2001.
Dalvit et al. Reliable high-throughput functional screening with 3-FABS. Drug Discovery Today 2004, 9, 595-602.
Dasgupta et al. Lipophilization of Somatostatin Analog RC-160 Improves its Bioactivity and Stability Pharmaceut. Res. 1999, 16:1047-1053.
Dasgupta et al. N-Terminal Acylation of Somatostatin Analog with Long Chain Fatty Acids Enhances its Stability and Anti-Proliferative Activity in Human Breast Adenocarcinoma Cells. Biol. Pharm. Bull. 2002. 25:29-36.
Durand et al. Synthesis and preliminary biological evaluations of ionic and nonionic amphiphilic alpha-phenyl-N-tert-butylnitrone derivatives. J. Med. Chem. 2003, 46, 5230-5237.
Gariepy et al. Vectorial delivery of macromolecules into cells using peptide-based vehicles. Trends in Biotech. 2001, 19,21-28.
Gentry et al. The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides. 1999, 20, 1229-1238.
Gerebtzoff et al. Chem. BioChem. Chembiochem. 2004. 5(5):676-84.
Gerig et al. Binding of 5-fluorol-tryptophan to human serum albumin. J. Am. Chem. Soc. 1980,102,4267-4268.
Hsieh et al. Long-acting angiotensin II inhibitors containing hexafluorovaline in position 8. J. Med. Chem. 1987,30,1097-1100.
Hunter et al. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clin. Endocrin. 1999, 50,245-251.
Jiang et al. Asymmetric synthesis of both enantiomers of anti-4,4,4-trifluorothreonine and 2-amino-4,4,4-trifluorobutanoic acid. J. Org. Chem.68,7544-7547,2003.
Jiang et al. Synthesis of the Four Stereoisomers of N-Fmoc-O-t-Bu-4,4,4-trifluorothreonine. Biopolymers. 2005. 80(4):527.
Jiang et al. The Synthesis of a Geminally Perfluoro-tert-butylatedâ-Amino Acid and its Protected Forms as a Potential Pharmacokinetic Modulator and Reporter for Peptide-Based Pharmaceuticals J. Org. Chem. 2007, 72, 1464-1467.
Kim et al. Structure and Transport Properties of a Novel, Heavily Fluorinated Carbohydrate Analogue. J. Am. Chem. Soc. 1998, 120:9082-9083.
Kommuru et al. Effect of chiral enhancers on the permeability of optically active and racemic metoprolol across hairless mouse skin. Chirality, I I, 536-540, 1999. 31.
Kovacs et al. Determination of intrinsic hydrophilicity/hydrophobicity of amino acid side chains in peptides in the absence of nearest-neighbor or conformational effects. Biopolymers, 2006, 84, 283-297.
Krause et al. Synthesis, X-ray crystallography, and pharmacokinetics of novel azomethine prodrugs of (R)-alpha-methylhistamine: highly potent and selective histamine H3 receptor agonists. J. Med. Chem. 1995,38,4070-4079.
Lien et al. Therapeutic Peptides. Trends in Biotech. 2003, 21, 556-562.
Merlo et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin. Cancer Res. 1999, 5,1025-1033.
Naarmann et al. Fluorinated interfaces drive self-association of transmembrane alpha helices in lipid bilayers. Chem. Int. Ed. 2006,45,2588-2591.
Neimz et al. Self-association and membrane-binding behavior of melittins containing trifluoroleucine. J. Am. Chem. Soc. 2001, 123, 7407-7413.
Ortial et al. Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents. J. Med. Chem. 2006,49, 2812-2820.
Pardridge, W. Vector-mediated peptide delivery to the brain. M.Adv. Drug Del. Rev. 1995, 15, 109-146.
Park et al. Metabolism of fluorine-containing drugs. Ann. Rev. Pharmacol. Toxicol. 2001, 41, 443-470.
Reubi, J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev. 24, 389-427,2003.
Rubenstein et al. Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J. Med. Chem. 2001,44, 3599-3605.
Rueter et al. Synthesis and biological activities of sandostatin analogs containing stereochemical changes in positions 6 or 8. Biopolymers, 53, 497-505,2000.
Schottelius et al. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogs by variation of peptide net charge and carbohydration chemistry. Bioconj. Chem. 2005, 16(2), 429-437.
Schumacher et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. Apr. 2002;29(4):486-93.
Schweizer et al. A fluorine scan at the catalytic center of thrombin: C—F, C—OH, and C—OMe bioisosterism and fluorine effects on pKa and log D values. ChemMedChem, 2006, 6:611-621.
Sebesta et al. Facile Preparation of Perfluoro-tert-butyl Ethers by the Mitsunobu Reaction. J. Org. Chem. 1996, 61, 361-362.
Smith et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion, 62(Suppl 1) 69-72.2000.
Undevia et al. J. Pharmacokinetic Variability of Anticancer Agents. Nat. Rev. Cancer 2005,5, 447-458.
Wester et al. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur. J. Nucl. Med. Mol. Imaging 2002, 29(1), 28-38.
Witt et al. CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier. AAPS Journal. 2006; 8(1): E76-E88. DOI: 10.1208/aapsj080109.
Wulbrand et al. A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes. Cancer, 2002, 1293-1297.
Yu et al. Increasing fluorous partition coefficients by solvent tuning. Org. Lett. 2005, 7, 3677-3680.
Yu et al. Investigation of electrostatic interactions in two-stranded coiled-coils through residue shuffling. Biophys. Chem. 1996, 59: 299-314.
Yu et al. Ion pairs significantly stabilize coiled-coils in the absence of electrolyte. J. Mol. Biol. 1996,255, 367-372.
Zlokovic, B. V., Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm. Res. 1995, 12, 1395-1406.
Jiang Zhong-Xing
Yu Bruce (Yihua)
Ballard Spahr LLP
Gudibande Satyanarayana
Tsang Cecilia J
University of Utah Foundation
LandOfFree
Highly fluorinated β-amino acids and methods of making... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Highly fluorinated β-amino acids and methods of making..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Highly fluorinated β-amino acids and methods of making... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289431